A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors

Part of paid clinical trials in East Hanover, New Jersey.

Sponsor
Novartis Pharmaceuticals
Study ID
NCT07512063
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The aim of this study was to evaluate patient profiles, treatment patterns, and outcomes of hormone receptor positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer (mBC) patients treated with a 1L cyclin dependent kinase 4/6 inhibitor (CDK4/6i) in the real-world setting.

Key Dates

Start date
Oct 8, 2024
Status verified
Mar 2026
Primary completion
Mar 17, 2025
Completion
Mar 17, 2025

Study Design

Enrollment
480 participants (actual)

Arms

  • Arm: CDK4/6i Cohort
    Adult HR+/HER2- mBC patients treated with 1L ribociclib, palbociclib, or abemaciclib.

Primary Outcome Measure

Number and Percentage of Patients Treated With 1L Ribociclib by Demographic Category [ Time Frame: Baseline ]

Locations (1)

FacilityCityStateZIPSite coordinators
NovartisEast HanoverNew Jersey07936-

Find similar trials in East Hanover, NJ

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Novartis· East Hanover, NJ

Related Studies